[开放获取]    中国关节病型银屑病诊疗共识（2020）

doi:10.35541/cjd.20200369

Abstract

Abstract: 【Abstract】 Psoriasis arthopathica, also known as psoriatic arthritis, is a special subtype of psoriasis. It manifests as varying degrees of peripheral and axial joint involvement, which seriously affects the life quality of patients. In recent years, rapid progress has been achieved in its diagnosis and treatment, especially the emergence of biologics has significantly improved the treatment outcome. Based on the latest domestic and international guidelines, and combined with the availability of diagnostic and therapeutic methods in China, the consensus focuses on clinical manifestations, classification, imaging and laboratory tests, diagnostic criteria and treatment of psoriasis arthropathica, providing a reference for the diagnosis and treatment of psoriasis arthropathica in clinical practice.

Key words: Arthritis, psoriatic, Diagnosis, Clinical protocols, Expert consensus

Writing committee expert group on “diagnosis and treatment of psoriasis arthropathica: an expert consensus statement in China”. Diagnosis and treatment of psoriatic arthritis: an expert consensus statement in China（2020）[J]. Chinese Journal of Dermatology, 2020, 53(8): 585-595.doi:10.35541/cjd.20200369

References ［40］

［1］	Yang Q, Qu L, Tian H, et al. Prevalence and characteristics of psoriatic arthritis in Chinese patients with psoriasis［J］. J Eur Acad Dermatol Venereol, 2011,25（12）:1409⁃1414. doi: 10.1111/ j.1468⁃3083.2011.03985.x.
［2］	Jo SJ, Foley P, Oakley SP, et al. Initial assessment of the early arthritis for psoriatic patients diagnostic questionnaire in dermatology clinics in Australia, Korea and China［J］. Int J Rheum Dis, 2019,22（8）:1512⁃1520. doi: 10.1111/1756⁃185X. 13604.
［3］	Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis［J］. N Engl J Med, 2017,376（10）:957⁃970. doi: 10.1056/NEJMra150 5557.
［4］	Zhang A, Kurtzman D, Perez⁃Chada LM, et al. Psoriatic arthritis and the dermatologist: an approach to screening and clinical evaluation［J］. Clin Dermatol, 2018,36（4）:551⁃560. doi: 10.1016/ j.clindermatol.2018.04.011.
［5］	Kerschbaumer A, Fenzl KH, Erlacher L, et al. An overview of psoriatic arthritis ⁃ epidemiology, clinical features, pathophysiology and novel treatment targets［J］. Wien Klin Wochenschr, 2016,128（21⁃22）:791⁃795. doi: 10.1007/s00508⁃016⁃1111⁃9.
［6］	Stuart PE, Nair RP, Tsoi LC, et al. Genome⁃wide association analysis of psoriatic arthritis and cutaneous psoriasis reveals differences in their genetic architecture［J］. Am J Hum Genet, 2015,97（6）:816⁃836. doi: 10.1016/j.ajhg.2015.10.019.
［7］	Haroon M, Winchester R, Giles JT, et al. Certain class I HLA alleles and haplotypes implicated in susceptibility play a role in determining specific features of the psoriatic arthritis phenotype［J］. Ann Rheum Dis, 2016,75（1）:155⁃162. doi: 10.1136/annrheumdis⁃2014⁃205461.
［8］	Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis［J］. Lancet, 2018,391（10136）:2273⁃2284. doi: 10.1016/S0140⁃6736（18）30830⁃4.
［9］	Shin D, Kim HJ, Kim DS, et al. Clinical features of psoriatic arthritis in Korean patients with psoriasis: a cross⁃sectional observational study of 196 patients with psoriasis using psoriatic arthritis screening questionnaires［J］. Rheumatol Int, 2016,36（2）:207⁃212. doi: 10.1007/s00296⁃015⁃3365⁃3.
［10］	Langenbruch A, Radtke MA, Krensel M, et al. Nail involvement as a predictor of concomitant psoriatic arthritis in patients with psoriasis［J］. Br J Dermatol, 2014,171（5）:1123⁃1128. doi: 10. 1111/bjd.13272.
［11］	Klaassen KM, Ploegmakers MJ, van de Kerkhof PC, et al. Subclinical enthesitis in nail psoriasis patients: a case⁃control study［J］. J Dtsch Dermatol Ges, 2017,15（4）:405⁃412. doi: 10. 1111/ddg.13222.
［12］	Scriffignano S, Perrotta FM, De Socio A, et al. Role of comorbidities in spondyloarthritis including psoriatic arthritis［J］. Clin Rheumatol, 2019,38（1）:3⁃10. doi: 10.1007/s10067⁃018⁃4332⁃7.
［13］	Haroon M, FitzGerald O. Psoriatic arthritis: complexities, comorbidities and implications for the clinic［J］. Expert Rev Clin Immunol, 2016,12（4）:405⁃416. doi: 10.1586/1744666X. 2016.1139453.
［14］	Eder L, Aydin SZ. Imaging in psoriatic arthritis⁃insights about pathogenesis of the disease［J］. Curr Rheumatol Rep, 2018,20（12）:77. doi: 10.1007/s11926⁃018⁃0793⁃6.
［15］	Lin Z, Wang Y, Mei Y, et al. High⁃frequency ultrasound in the evaluation of psoriatic arthritis: a clinical study［J］. Am J Med Sci, 2015,350（1）:42⁃46. doi: 10.1097/MAJ.0000000000000504.
［16］	Kaeley GS, Eder L, Aydin SZ, et al. Enthesitis: a hallmark of psoriatic arthritis［J］. Semin Arthritis Rheum, 2018,48（1）:35⁃43. doi: 10.1016/j.semarthrit.2017.12.008.
［17］	Maldonado⁃Ficco H, Sheane BJ, Thavaneswaran A, et al. Magnetic resonance imaging in psoriatic arthritis: a descriptive study of indications, features and effect on treatment change［J］. J Clin Rheumatol, 2017,23（5）:243⁃245. doi: 10.1097/RHU.0000000000000558.
［18］	Moll JM, Wright V. Psoriatic arthritis［J］. Semin Arthritis Rheum, 1973,3（1）:55⁃78. doi: 10.1016/0049⁃0172（73）90035⁃8.
［19］	Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study［J］. Arthritis Rheum, 2006,54（8）:2665⁃2673. doi: 10.1002/art.21972.
［20］	Coates LC, Kavanaugh A, Mease PJ, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis［J］. Arthritis Rheumatol, 2016,68（5）:1060⁃1071. doi: 10.1002/art.39573.
［21］	Singh JA, Guyatt G, Ogdie A, et al. 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis［J］. Arthritis Rheumatol, 2019,71（1）:5⁃32. doi: 10.1002/art.40726.
［22］	Wilsdon TD, Whittle SL, Thynne TR, et al. Methotrexate for psoriatic arthritis［J］. Cochrane Database Syst Rev, 2019,1:CD012722. doi: 10.1002/14651858.CD012722.pub2.
［23］	Gisondi P, Altomare G, Ayala F, et al. Consensus on the management of patients with psoriatic arthritis in a dermatology setting［J］. J Eur Acad Dermatol Venereol, 2018,32（4）:515⁃528. doi: 10.1111/jdv.14741.
［24］	中华医学会皮肤性病学分会, 中国医师协会皮肤科医师分会, 中国中西医结合学会皮肤性病专业委员会. 中国银屑病生物治疗专家共识（2019）［J］. 中华皮肤科杂志, 2019,52（12）:863⁃871. doi: 10.35541/cjd.20190892.
［25］	Menter A, Strober BE, Kaplan DH, et al. Joint AAD⁃NPF guidelines of care for the management and treatment of psoriasis with biologics［J］. J Am Acad Dermatol, 2019,80（4）:1029⁃1072. doi: 10.1016/j.jaad.2018.11.057.
［26］	McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double⁃blind, placebo⁃controlled PSUMMIT 1 trial［J］. Lancet, 2013,382（9894）:780⁃789. doi: 10.1016/S0140⁃6736（13）60594⁃2.
［27］	Kavanaugh A, Puig L, Gottlieb AB, et al. Maintenance of clinical efficacy and radiographic benefit through two years of ustekinumab therapy in patients with active psoriatic arthritis: results from a randomized, placebo⁃controlled phase III trial［J］. Arthritis Care Res （Hoboken）, 2015,67（12）:1739⁃1749. doi: 10.1002/acr.22645.
［28］	van der Heijde D, Landewé RB, Mease PJ, et al. Secukinumab provides significant and sustained inhibition of joint structural damage in a phase III study of active psoriatic arthritis［J］. Arthritis Rheumatol, 2016,68（8）:1914⁃1921. doi: 10.1002/art.39685.
［29］	Coates LC, Kishimoto M, Gottlieb A, et al. Ixekizumab efficacy and safety with and without concomitant conventional disease⁃modifying antirheumatic drugs （cDMARDs） in biologic DMARD （bDMARD）⁃naïve patients with active psoriatic arthritis （PsA）: results from SPIRIT⁃P1［J/OL］. RMD Open, 2017,3（2）:e000567. doi: 10.1136/rmdopen⁃2017⁃000567.
［30］	Mease P, Hall S, FitzGerald O, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis［J］. N Engl J Med, 2017,377（16）:1537⁃1550. doi: 10.1056/NEJMoa1615975.
［31］	Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors［J］. N Engl J Med, 2017,377（16）:1525⁃1536. doi: 10.1056/NEJMoa1615977.
［32］	Ogdie A, Coates LC, Gladman DD. Treatment guidelines in psoriatic arthritis［J］. Rheumatology （Oxford）, 2020,59（Supplement_1）:i37⁃37i46. doi: 10.1093/rheumatology/kez383.
［33］	Zhao J, Di T, Wang Y, et al. Multi⁃glycoside of Tripterygium wilfordii Hook. f. ameliorates imiquimod⁃induced skin lesions through a STAT3⁃dependent mechanism involving the inhibition of Th17⁃mediated inflammatory responses［J］. Int J Mol Med, 2016,38（3）:747⁃757. doi: 10.3892/ijmm.2016.2670.
［34］	Zhang C, Sun PP, Guo HT, et al. Safety profiles of Tripterygium wilfordii Hook F: a systematic review and meta⁃analysis［J］. Front Pharmacol, 2016,7:402. doi: 10.3389/fphar.2016.00402.
［35］	Haroon M, Gallagher P, FitzGerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis［J］. Ann Rheum Dis, 2015,74（6）:1045⁃1050. doi: 10.1136/annrheumdis⁃2013⁃204858.
［36］	Smolen JS, Schöls M, Braun J, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force［J］. Ann Rheum Dis, 2018,77（1）:3⁃17. doi: 10.1136/annrheumdis⁃2017⁃211734.
［37］	Coates LC, Moverley AR, McParland L, et al. Effect of tight control of inflammation in early psoriatic arthritis （TICOPA）: a UK multicentre, open⁃label, randomised controlled trial［J］. Lancet, 2015,386（10012）:2489⁃2498. doi: 10.1016/S0140⁃6736（15）00347⁃5.
［38］	Schoels M, Aletaha D, Funovits J, et al. Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis［J］. Ann Rheum Dis, 2010,69（8）:1441⁃1447. doi: 10.1136/ard.2009.122259.
［39］	戴生明, 毕新岭. 银屑病关节炎［M］. 北京: 人民卫生出版社, 2018:175⁃181.
［40］	Anderson JJ, Baron G, van der Heijde D, et al. Ankylosing spondylitis assessment group preliminary definition of short⁃term improvement in ankylosing spondylitis［J］. Arthritis Rheum, 2001,44（8）:1876⁃1886. doi: 10.1002/1529⁃0131（200108）44:83.0.CO;2⁃F.

[1]	Wang Yuqian, Qiao Jianjun, Fang Hong. Comparison of the latest Chinese and international guidelines/consensus on diagnosis and treatment of alopecia areata [J]. Chinese Journal of Dermatology, 2023, 56(9): 885-888.
[2]	Yuan Xingang, Ni Sili, Zhang Jian, Luo Xiaoyan, Wang Hua. Improving diagnosis and treatment of melanocytic nevi in children: an urgent need [J]. Chinese Journal of Dermatology, 2023, 56(8): 782-786.
[3]	China Dermatologist Association. Guidance on application of moisturizers and emollients: an expert consensus （2023） [J]. Chinese Journal of Dermatology, 2023, 56(8): 711-717.
[4]	Committee on Psoriasis, Chinese Society of Dermatology. Guideline for the diagnosis and treatment of psoriasis in China （2023 edition） [J]. Chinese Journal of Dermatology, 2023, 56(7): 573-625.
[5]	Mi Shuhong, Yu Yanqin, Hao Jinqi, Li Wei, Zhang Yang, Jia Ximei, Huang Yuxian, Sun Huaiyu, Shi Jihai. Analysis of imaging characteristics of papulopustular rosacea by high-frequency ultrasound combined with color Doppler flow imaging [J]. Chinese Journal of Dermatology, 2023, 56(6): 540-544.
[6]	Liang Yunsheng, Li Zhanhong, Wu Yibei. Progress in the treatment of chronic spontaneous urticaria: insights from the changes in the understanding of its pathogenesis [J]. Chinese Journal of Dermatology, 2023, 56(6): 552-558.
[7]	Chen Qiquan, Yang Xianjie, Wang Wenwen, Liang Gaopeng, Song Zhiqiang . Development and application of clinical assessment tools for cholinergic urticaria [J]. Chinese Journal of Dermatology, 2023, 56(6): 563-566.
[8]	Chen Qiquan, Yang Xianjie, Gu Heng, Xu Jinhua, Hao Fei, Yao Xu, Song Zhiqiang. Construction of “Expert consensus on diagnosis and treatment of chronic inducible urticaria in China （2023）” based on the Delphi method [J]. Chinese Journal of Dermatology, 2023, 56(6): 534-539.
[9]	Immunology Group, Chinese Society of Dermatology. Expert consensus on diagnosis and treatment of chronic inducible urticaria in China （2023） [J]. Chinese Journal of Dermatology, 2023, 56(6): 479-488.
[10]	Writing Committee Expert Group on “Treatment of mycosis fungoides: a Chinese expert consensus （）”. Treatment of mycosis fungoides: a Chinese expert consensus （2023） [J]. Chinese Journal of Dermatology, 2023, 56(5): 402-409.
[11]	Hu Qingjie, Zhou Min, Yao Xu. Analysis of clinical characteristics of 36 patients with pyoderma gangrenosum and comparison between the PARACELSUS score and Delphi criteria for their diagnosis [J]. Chinese Journal of Dermatology, 2023, 56(5): 410-414.
[12]	Committee on Sexually Transmitted Diseases, China Dermatologist Association. Expert consensus on clinical management of serofast state in syphilis （2023） [J]. Chinese Journal of Dermatology, 2023, 56(5): 383-388.
[13]	Jia Weixue, Li Chengrang. Comparison of Chinese and international guidelines and consensus for the diagnosis and treatment of vitiligo [J]. Chinese Journal of Dermatology, 2023, 56(5): 471-475.
[14]	Wang Min, He Pingxiu, Cheng Lifang, Hong Kechun, Ai Yong. A case of meningothelial hamartoma of the scalp [J]. Chinese Journal of Dermatology, 2023, 56(5): 449-450.
[15]	Luo Shuaihantian, Long Hai, Lu Qianjin, . Research advances in systemic lupus erythematosus in 2022 [J]. Chinese Journal of Dermatology, 2023, 56(3): 266-269.

Diagnosis and treatment of psoriatic arthritis: an expert consensus statement in China（2020）

PDF

Knowledge

Abstract

Cite this article

share this article

References ［40］

Related Articles 15

Metrics

Comments

Recommended 10